[ad_1]
In late August, AstraZeneca announced the start of antibody testing to treat the disease. "COVID-19", Caused by the new corona virus.
AstraZeneca said it had started testing an antibody-based treatment to prevent and treat Covid-19 disease, noting that the first participants in the trials took doses.
The British company added that the first phase of the trials will focus on evaluating whether it is a drug "ZD 7442"It, which includes two types of monoclonal antibodies, is safe and is tolerated by the body in up to 48 healthy participants between the ages of 18 and 55, according to Reuters.
If the first trials to be conducted in Britain are positive, AstraZeneca will embark on a larger phase of testing the drug as a preventive treatment and as a drug for patients who have contracted it.
In June, the company, which is listed on the London Stock Exchange, received $ 23.7 million in funding from United States government agencies to develop antibiotic-based treatments for Covid-19.
And previous clinical trials in volunteers showed that a vaccine "AstraZeneca" Your epidemic "COVID-19"It was safe and generated immunity among those who contracted it.
The named vaccine has not caused "AZD1222" No side effects, no antibody damage and response "T cells"According to the results published by the magazine "Lancet" Doctor, according to what he reported "Reuters".
Oxford University, which is developing the vaccine in cooperation with AstraZenka, said the experiments showed that volunteers who received the second dose appeared to have antibodies and also formed T cells that help strengthen the immune system in the human body.
“>
The group said in a statement that “in the framework of global randomized clinical trials of the Oxford virus vaccine, our standard evaluation process has been activated and we have voluntarily suspended vaccination processes to allow a review of safety data by part of an independent committee. ““.
And AstraZeneca had announced in late August the start of antibody trials to treat the “Covid-19” disease, caused by the new Corona virus.
AstraZeneca said it had started testing an antibody-based treatment to prevent and treat Covid-19 disease, noting that the first participants in the trials took doses.
The British company added that the first phase of the trials will focus on evaluating whether the drug “AZD 7442”, which includes two types of monoclonal antibodies, is safe and tolerated by the body in up to 48 healthy participants between the ages of 18 and 55. years. According to Reuters.
If the first trials to be conducted in Britain are positive, AstraZeneca will embark on a larger phase of testing the drug as a preventive treatment and as a drug for patients who have contracted it.
In June, the company, which is listed on the London Stock Exchange, received $ 23.7 million in funding from United States government agencies to develop antibiotic-based treatments for Covid-19.
And previous clinical trials in volunteers showed that the “AstraZeneca” vaccine for the “Covid-19” epidemic was safe and generated immunity among those who received it.
The vaccine, called “AZD1222”, did not cause any side effects, did not damage antibodies and the “T-cell” response, according to results published by the medical journal “Lancet”, according to “Reuters”.
Oxford University, which is developing the vaccine in cooperation with AstraZenka, said the experiments showed that volunteers who received the second dose appeared to have antibodies and also formed T cells that help strengthen the immune system in the human body.
[ad_2]
